Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Eyes $3.7M in Proceeds from Securities Purchase Deal

NEW YORK (GenomeWeb) – Interpace Diagnostics said after the close of the market on Tuesday that it has entered into a securities purchase deal with certain institutional investors that is expected to raise $3.7 million in net proceeds.

The investors have agreed to purchase 375,000 shares of Interpace's common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share. The offering is expected to close on or about Jan. 6.

Net proceeds from the deal will be used for working capital, repayment of debt, and general corporate purposes. Maxim Group served as the exclusive placement agent for the offering.

Interpace entered into a stock purchase deal last month to raise $1.7 million. The company also effected a 1-for-10 reverse stock split last week.

 

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.